Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic
  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Neurophth Closes $60 Million C Round for Ophthalmic Gene Therapies

Neurophth Therapeutics, a Wuhan-San Diego ophthalmic gene therapy company, closed a more-than $60 million Series C financing from China and international investors. Neurophth's lead candidate is the first AAV2 gene therapy IND application approved in  China . The company said it would use the funds to advance its lead therapy for Leber hereditary optic neuropathy (LHON), a genetic blindness condition, outside of China after starting China trials in June 2021. The C round was led by CMG-SDIC Capital and Sequoia Capital China. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.